DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Summary for Patent: 9,358,232
|Title:||Methods for treating cancer using TOR kinase inhibitor combination therapy|
|Abstract:||Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide to a patient having a cancer.|
|Inventor(s):||Hege; Kristen Mae (Burlingame, CA), Chopra; Rajesh (Summit, NJ)|
|Assignee:||Signal Pharmaceuticals, LLC (San Diego, CA)|
|Patent Claims:||1. A method for treating diffuse large B-cell lymphoma, comprising administering an effective amount of a TOR kinase inhibitor in combination with an effective amount of
N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide, or a pharmaceutically acceptable salt thereof, to a patient having diffuse large B-cell lymphoma, wherein the TOR kinase inhibitor is
7-(6-(2-hydroxypropan-2-yl)-pyridin-3-yl)-1-((1r,4r)-4-methoxycyclohexyl)- -3,4-dihydropyrazino-[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer, tautomer or isotopologue thereof.
2. The method of claim 1, wherein the diffuse large B-cell lymphoma is associated with the pathways involving mTOR, PI3K, or Akt kinases and mutants or isoforms thereof.
3. The method of claim 1, wherein the TOR kinase inhibitor is administered in combination with a besylate salt of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide.
4. The method of claim 1, wherein the TOR kinase inhibitor is administered in combination with the free base of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phen- yl)acrylamide.
5. The method of claim 1, further comprising the administration of an anti-CD20 antibody.
6. The method of claim 5, wherein anti-CD20 antibody is rituximab.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Genentech||RITUXAN||rituximab||VIAL||103705||001||1997-11-26||Request a Trial||Signal Pharmaceuticals, LLC (San Diego, CA)||2033-04-17||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Publication Date|
|World Intellectual Property Organization (WIPO)||2014172430||Oct 23, 2014|
|United States of America||2014314751||Oct 23, 2014|
|Taiwan||201521725||Jun 16, 2015|
|Mexico||2015014455||Jul 21, 2016|
|>Country||>Patent Number||>Publication Date|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.